Notes to the consolidated statements of income

Schedule of disaggregation of revenue by categories

Disaggregation of revenue by categories

in € K



	For the three months ended		For the nine months ended
	September 30,		September 30,
	2026	2025	2026	2025
Care Delivery	3,491,930	3,401,706	10,263,812	10,229,217
Thereof: U.S.	2,920,216	2,841,894	8,582,459	8,550,486
Thereof: International	571,714	559,812	1,681,353	1,678,731
Value-Based Care	536,600	575,517	1,563,107	1,610,703
Care Enablement	1,451,438	1,360,660	4,121,490	4,075,435
Inter-segment eliminations	(543,226)	(453,033)	(1,538,954)	(1,357,338)
Total	4,936,742	4,884,850	14,409,455	14,558,017

Schedule of amounts included in other operating income

Other operating income

in € K



		For the three months ended				For the nine months ended
		September 30,				September 30,
		2026		2025		2026		2025
Foreign exchange gains		72,552		36,200		279,394		301,410
Gains on right-of-use assets, from the sale of fixed assets, clinics and investments		1,961		1,097		15,654		7,668
Revaluation of certain investments ⁽¹⁾		16		(178)		3,273		7,328
Income from strategic transactions and programs		19,871		2,405		34,135		10,342
Changes in fair value of the derivatives embedded in Virtual Power Purchase Agreements (vPPAs)		10,858		2,010		14,969		30,605
Other		11,107		14,543		47,331		39,883
Other operating income		116,365		56,077		394,756		397,236

(1)Primarily driven by the remeasurement of the Company’s investment in Humacyte, Inc. for the three and nine months ended September 30, 2026 and 2025.

Schedule of expenses from strategic transactions and programs

Expenses from strategic transactions and programs

in € K



		For the three months ended			For the nine months ended
		September 30,			September 30,
		2026		2025	2026		2025
Impairment of intangible and tangible assets⁽¹⁾		74,531		211	198,226		12,679
Legacy Portfolio Optimization		72,646		(150)	72,873		11,997
FME25+ Program		1,885		361	125,353		682
Impairment resulting from the measurement of assets held for sale		237		(75)	237		8,789
Legacy Portfolio Optimization		237		(75)	237		8,789
Loss from the sale of business		(3)		43,444	647		43,444
Legacy Portfolio Optimization		(3)		43,444	647		43,444
Other⁽²⁾		44,962		9,645	86,209		29,172
FME25+ Program		(513)		—	21,268		—
Legacy Portfolio Optimization		45,475		9,429	64,941		27,494
Legal Form Conversion Costs		—		216	—		1,678
Expenses from strategic transactions and programs		119,727		53,225	285,319		94,084

(1)	For the three and nine months ended September 30, 2026 and 2025, the amounts primarily relate to costs of revenue and, to a lesser extent, to selling, general and administrative expense.

(2)

For the three and nine months ended September 30, 2026, the amounts relate primarily to costs of revenue and, to a lesser extent, to selling, general and administrative expense. For the three and nine months ended September 30, 2025, the amounts primarily relate to selling, general and administrative expense and, to a lesser extent, to costs of revenue.

Schedule of number of shares acquired in the context of the share buyback programs

Treasury Stock



						Total number of
						shares purchased		Maximum value of
						and retired		shares that may yet
						as part of publicly		be purchased under
		Total number of		Average price per		announced plans or		the plans or
Period		shares purchased		share		programs		programs
				in €				in € K

August 2025		2,084,733		42.68		2,084,733		511,021
September 2025		1,479,790		42.45		1,479,790		448,210
October 2025		788,260		46.38		788,260		411,651
November 2025		4,164,232		41.10		4,164,232		240,485
December 2025		5,607,549		40.26		5,607,549		—
January 2026		2,898,373		37.29		2,898,373		305,474
February 2026		2,596,794		39.67		2,596,794		202,449
March 2026		3,705,233		38.72		3,705,233		58,973
April 2026		1,523,855		38.67		1,523,855		—
May 2026		155,000		37.15		155,000		594,242
June 2026		2,299,945		39.49		2,299,945		503,409
July 2026		1,178,833		41.86		1,178,833		454,065
August 2026		3,205,260		40.84		3,205,260		323,153
September 2026		2,216,227		38.92		2,216,227		236,894
Total repurchased shares ⁽¹⁾		33,904,084		40.17		33,904,084		236,894

Cancellation of repurchased shares		24,848,819		40.19		24,848,819		—

Treasury Stock held on September 30, 2026		9,055,265		40.10		9,055,265		—

(1)

The difference between the maximum value of shares that may yet be purchased under the Company’s share buyback program and the liability for such shares of €1,613 as of September 30, 2026 results from the timing of payments made for share repurchases on a weekly basis. The difference is recorded in the consolidated statements of equity within Additional paid-in capital.